BXPLANT to Present CDRO-Based Drug Development Model at KIC 2025

BXPLANT announced on the 15th that it will participate in the ‘2025 KoNECT·MOHW·MFDS International Conference (KIC)’ to present a CDRO-based drug development model encompassing the full cycle of clinical development.

KIC is Asia’s largest international clinical trial conference, co-hosted by the Ministry of Health and Welfare (MOHW) and the Ministry of Food and Drug Safety (MFDS). The conference will be held at Lotte Hotel Seoul from the 22nd to 24th, marking its 11th anniversary this year.

Approximately 1,500 domestic and international experts gather annually to share insights on global drug development, digital transformation in clinical trials, and regulatory change response strategies.

CEO Heesun Kim’s Leadership Role

At this event, CEO Heesun Kim will serve as the Program Committee Chair for the Drug Development track, contributing to the overall planning process and showcasing a successful drug development model in partnership with CDRO (Contract Development and Research Organization).

In particular, CEO Kim will chair the session ‘S8. Transforming Regulatory Landscape: Innovation, Partnership, and Global Alignment’ on the 23rd, leading discussions on global regulatory innovation and collaboration strategies.

BXPLANT Booth and Services

Additionally, BXPLANT will operate a promotional booth throughout the event to introduce its comprehensive CDRO model, which encompasses all stages including: preclinical R&D consulting, clinical strategy development CRO execution and global business support.

The booth will feature real project-based case studies and offer first-come, first-served 1:1 clinical development consultations, allowing visitors to receive expert advice on-site.

A BXPLANT representative emphasized, “BXPLANT supports our clients’ successful drug development through a CDRO model that goes beyond simple clinical trial execution to provide strategic clinical development partnership. Our participation in KIC 2025, along with CEO Kim’s roles as Committee Chair and Session Chair, will serve as an important opportunity to showcase Korea’s clinical development capabilities to the global market.”